Sangeetha Reddy retweeted
#AACR25, capturing the last night at AACR grantee award reception along with @utswcancer colleague @smreddymd ! Managed to take a photo with the one and only @AACR_CEO !Thanks the grant support from @AACR @kidneycan
Sangeetha Reddy retweeted
Big congratulations @smreddymd @utswcancer !!
We congratulate Sangeetha Reddy, MD, recipient of a 2024 Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in Partnership with Pelotonia & AACR. Dr. Reddy will study the impact of CD40 agonists on the myeloid CD8 T cell axis.
@VictoriasSecret @Pelotonia
Sangeetha Reddy retweeted
#SABCS23 | Poster PO2-27-12 | Genomic determinants of benefit to nivolumab + low dose ipilimumab among patients with hypermutated HER2- #MBC: Results of #NIMBUS trial. #MetastaticBreastCancer @DrRBarroso @stolaney1 @nlinmd @nabihahtayob @emittendorfmd @RMJesel @smreddymd
Sangeetha Reddy retweeted
After my wonderful experience at @MDAndersonNews, I've realized there is a robust academic life beyond it. Certainly, those who remain at or return to MDA also enjoy fulfilling careers. I've learned that various cancer centers contribute uniquely to breast cancer research. #SABCS23 – at San Antonio, TX
Sangeetha Reddy retweeted
Tumor Agnostic Approaches to Care: @VivekSubbiah, Joshua Z. Drago, @DrMiaLevy, and Marleen Kok addressed this topic in a Clinical Workshop moderated by Sangeetha M. Reddy this afternoon at #SABCS23.
@lab_kok @smreddymd @AACR @UTHealthSAMDA @OncoAlert
Sangeetha Reddy retweeted
The cancer #immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. Check out this revised review that helps better understand the successes & failures of cancer #immunotherapy doi.org/10.1016/j.immuni.202…
Sangeetha Reddy retweeted
It is not uncommon for clinician scientists to be questioned whether they’re ‘real doctors’ or ‘true scientists’
Both
The secret to a long life as a clinician scientist is the same as a long marriage. Selective deafness
Great paper @ESMO_Open @DrJonLim
esmoopen.com/article/S2059-7…
Sangeetha Reddy retweeted
Highlighting the important role the innate immune system plays in immunotherapy, @smreddymd delivers an excellent lecture describing the rationale for augmenting CDK4/6i and ICB with dendritic cell therapy. #DAVAHawaiiBreast jitc.bmj.com/content/11/5/e0…
Starting Now: Immunotherapy in Breast Cancer - (Vaccine Strategies). Moderated by: Vered Stearns #DAVAHawaiiBreast
Sangeetha Reddy retweeted
Incredible presentation at #SABCS2022 on InteractPrint by Student Doctor Lily Xu from @ithinkichan Lab! Stellar mentorship by Dr. Chan to feature this rising star at a general session! Grateful for this incredible collaboration @smreddymd @utswcancer and excited for more to come!
Sangeetha Reddy retweeted
PD1-blockade back in the game for ER+ breast cancer! 🎊Congrats to PACE trialists. 👏👏Impressive OS for pts treated with avelumab, most important no special tox in contrast to Cm7A8 and abema/pembro. aPD1 vs aPDL1? #sabcs22. #bcsm @SABCSSanAntonio
Sangeetha Reddy retweeted
You don’t want to miss these sessions today! @smreddymd moderating “Modifying Tumor Response: Microbiome, Diet, and Fasting” from 1-2pm and @AriellaHanker presenting “Demystifying CDKs in Breast Cancer: Beyond CDK4/6” from 2-3pm at #SABCS22. @SABCSSanAntonio
Sangeetha Reddy retweeted
Sorry the pun 🥸🤡, but for me this was RIGHTly the most interesting data from the 1st day of #SABCS22.
Visceral crisis is a dramatic situation where chemo has always been the choice, but which ribo plus letrozole has shown to be more effective with less AEs
@OncoAlert #bcsm
Sangeetha Reddy retweeted
TALENT presented by @dradityabardia
Preop T-DXd +/- AI for ER+ HER2-low BC (6-8 cycles)
N=58
Response by imaging with T-DXd=68%, T-DXd+AI: 58%
1 pt with pCR, 5 with RCB1
16 pts still haven't had surgery
@OncoAlert #bcsm #SABCS22
Sangeetha Reddy retweeted
#SABCS22 Ian Krop presents the continued remarkable efficacy of TDXd in the later line HER2+ setting. 2deaths (0.5%) from ILD with total rate 10.4%. Best to use in 2nd line for optimal efficacy but it works well late! @OncoAlert
Sangeetha Reddy retweeted
Sara Hurvitz presents #DB03 update.
▪️CBR approaching 90% for TDXd, ORR >75%
▪️Discontinuations 21% TDXd vs. 10% TDM1, ILD 15.2% (no G4/5 events)
▪️PFS 6.8 mo vs. 28.8 months
▪️Reduced risk of death by 36%
#SABCS22 @OncoAlert
Sangeetha Reddy retweeted
My fantastic colleague @smreddymd leading a full spotlight poster session on cutting edge immunotherapy! #sabcs @utswcancer
Sangeetha Reddy retweeted
monarchE: Adj ET +/- abemaciclib x 2 yrs
Updated 4-year analysis
iDFS HR 0.664
OS HR 0.929
Benefits seen irrespective of Ki67
Important to see benefits of abemaciclib persist beyond the completion of tx
@OncoAlert #bscm #SABCS22 @professorSteph7
Sangeetha Reddy retweeted
BCI in SOFT: BCI risk was prognostic; BCI H/I was predictive of OFS benefit (low group has benefit, high group did not). More work needed to understand the biological explanation for this finding.
@OncoAlert #SABCS2022 #bcsm
Sangeetha Reddy retweeted
More from TailoRx #SABCS2022 benefit still seek in the higher score (21-25) premenopausal population but impossible to rule out impact of menopause. @OncoAlert






















































